Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy
Executive Summary
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
You may also be interested in...
Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder
After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.
Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Coronavirus Update: Regeneron's New Antibody Efficacy; Pfizer And Merck Strike US Contracts
Regeneron's antibody cocktail prevented deaths and mechanical ventilation in hospitalized patients on low-flow oxygen. Also, Pfizer and BioNTech will supply an additional 100m doses of the companies' COVID-19 vaccine to the US government for $1.95bn, while Merck & Co signed a contract for its COVID-19 treatment MK-7110.